by Véronique Diéras, Hyo S Han, Bella Kaufman, Hans
Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L Puhalla, Igor
Bondarenko, Mario Campone, Erik H Jakobsen, Mathilde Jalving, Cristina Oprean,
Marketa Palácová, Yeon Hee Park, Yaroslav Shparyk, Eduardo Yañez, Nikhil
Khandelwal, Madan G Kundu, Matthew Dudley, Christine K Ratajczak, David Maag,
Banu K Arun
The Lancet
Oncology: ARTICLES| VOLUME
21, ISSUE 10, P1269-1282, OCTOBER 01, 2020
The addition of veliparib to a highly active platinum
doublet, with continuation as monotherapy if the doublet were discontinued,
resulted in significant and durable improvement in progression-free survival in
patients with germline BRCA mutation-associated advanced breast cancer. These
data indicate the utility of combining platinum and PARP inhibitors in this
patient population.
